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Heritable changes to the transcriptome that are independent to changes in the genome are defined as epige-
netics. DNA methylation and posttranslational modifications of histones, such as acetylation/deacetylation
and methylation/demethylation of lysine residues, underlie these epigenetic phenomena, which impact on
many physiological processes. This perspective focuses on the emerging biology of histone methylation
and demethylation, highlighting how these reactions depend on metabolic coenzymes like S-adenosylme-
thionine, flavin adenine dinucleotide, and a-ketoglutarate. Furthermore, we illustrate that methyltranferases
and demethylases affect manymetabolic pathways. Despite the preliminary evidence that methyltranferases
and demethylases could link metabolic signals to chromatin and alter transcription, further research is indis-
pensable to consolidate these enticing observations.Introduction
Increased life expectancy in industrialized
countries goes hand in hand with a steady
progression of multifactorial diseases,
such as type 2 diabetes mellitus, obesity,
and cancer, which result from the
combined action of many genes and
environmental factors, such as diet or
exercise. Metabolic homeostasis is main-
tained by an intricate regulatory circuitry,
controlled to a large extent by transcrip-
tional mechanisms (Chawla et al., 2001;
Francis et al., 2003; Feige and Auwerx,
2007). Metabolism therefore represents
a sensitive indicator of the efficiency of
these transcriptional mechanisms. Tran-
scriptional control is achieved through
a complex molecular circuitry that
involves individual transcription factors,
the basal transcriptional machinery, and
multiprotein coregulatory complexes.
These coregulators fine tune transcription
and are proposed to act as metabolic
sensors, which translate changes in
metabolism into alterations in gene
expression by affecting the activity of
transcription factors, as well as changing
the structure of the epigenome (reviewed
by Smith and O’Malley, 2004; Spiegelman
and Heinrich, 2004; Rosenfeld et al.,
2006; Feige and Auwerx, 2007; Haberland
et al., 2009).
Within the eukaryotic cell nucleus,
genetic information in DNA is organized
in a highly conserved structural polymer,
termed chromatin, which supports andcontrols the functions of the genome.
The fundamental repeating unit of chro-
matin is the nucleosome, which consists
of 146 bp of DNA wrapped around an
octamer of core histone proteins (an
H3-H4 tetramer and two H2A-H2b
dimers) (reviewed by Laskowski and
Thornton, 2008). Linker histones of the
H1 class associate with DNA between
single nucleosomes establishing a higher
level of organization, the so-called ‘‘sole-
noid’’ helical fibers (Laskowski and
Thornton, 2008). Core histones are
evolutionarily conserved and consist of
a globular domain and a flexible charged
N-terminal tail, which is covalently modi-
fied by different enzymes mainly at
specific lysine and/or arginine residues.
Those modifications of the histone tail
include acetylation, phosphorylation,
methylation (Figure 1), and ubiquitination.
Together these histone modifications
compose the ‘‘histone code,’’ which
influences chromatin condensation and
gene transcription (reviewed by Jenu-
wein and Allis, 2001; Berger, 2007; Kou-
zarides, 2007; Ruthenburg et al., 2007).
Depending on nucleosome condensa-
tion, chromatin is more or less accessible
to different enzymes and proteins, most
of which regulate gene expression.
Euchromatin is generally referred to tran-
scriptionally active relaxed chromatin,
while the silent inaccessible chromatin
is called heterochromatin. Although
chromatin modifications have beenCell Metabolism 1divided into those that correlate with
activation and those that correlate with
repression of transcription, the truth is
likely to be that any given modification
can activate or repress genes depending
on the context (Vakoc et al., 2005;
Berger, 2007; Bernstein et al., 2007;
Kouzarides, 2007; Ruthenburg et al.,
2007).
Since the well-established role of DNA
methylation (reviewed by Suzuki and
Bird, 2008 and Ling and Groop, 2009)
and the emerging function of histone
acetyltransferases and deacetylases
(reviewed by Smith and O’Malley, 2004;
Spiegelman and Heinrich, 2004; Rose-
nfeld et al., 2006; Feige and Auwerx,
2007; Haberland et al., 2009) in the control
of metabolism has been recently re-
viewed, we focus here on the existing
evidence for a potential role of histone
methylation in metabolic adaptation.
Histone Methylation
and Demethylation in the Control
of Gene Expression
Histone methylation increases the
basicity and hydrophobicity of histone
tails and the affinity of certain proteins,
such as transcription factors, toward
DNA. There are three classes of histone
methyltransferase (HMTs) enzymes: SET
domain lysine methyltransferases, non-
SET domain lysine methyltransferases,
and arginine methyltransferases. All three
classes use S-adenosylmethionine (SAM)2, October 6, 2010 ª2010 Elsevier Inc. 321
Figure 1. Schematic Representation of Posttranslational Modifications of Histone Proteins with a Particular Focus on Histone Methylation
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(Smith and Denu, 2009). Lysine methyl-
transferases have striking target speci-
ficity, and they usually modify one single
lysine on a single histone and their output
can be either activation or repression of
transcription.
The SET domain-containing class of
methyltransferases is best characterized
and has been associated with metabolic
diseases (Lee et al., 2008b; El-Osta
et al., 2008, and Brasacchio et al.,
2009). The SET domain is an evolutionary
conserved domain, initially identified in
Drosophila PEV (positive effect variega-
tion) suppressor SU(VAR)39 (Tschiersch
et al., 1994), the polycomb group protein
Enhancer of zeste (Jones and Gelbart,
1993), and the trithorax group protein
Trithorax (Stassen et al., 1995). Although
the major role of these methyltrans-
ferases is the modulation of gene activity
via histone methylation and alteration of
chromatin structure (Rea et al., 2000),
they also target several nonhistone
proteins. In particular, the tumor sup-
pressors p53 (Chuikov et al., 2004;
Huang et al., 2010) and pRb (Munro
et al., 2010), and the estrogen receptor
a (Subramanian et al., 2008) are
substrates of SET-domain-containing
methyltransferases, while the peroxi-
some proliferator-activated receptor g
coactivator 1a is a substrate of the argi-322 Cell Metabolism 12, October 6, 2010 ª20nine methyltransferase CARM1 (Teyssier
et al., 2005).
For a number of years following the
discovery of HMTs, the existence of
histone demethylases (HDMs) was
contentious. The discovery of the first
HDM, lysine-specific demethylase 1
(LSD1) (Shi et al., 2004), led to the identifi-
cation of additional demethylases. These
HDMs are distinguished by the nature of
their demethylase domains, with distinct
reactions being catalyzed by the LSD1
domain and the JmjC (Jumonji C) domain
demethylases. LSD1 is a highly con-
served protein, homologous to other
FAD-dependent oxidases (like the mono-
amine oxidases involved in serotonin
metabolism), composed of two subdo-
mains: a FAD-binding and a substrate-
binding domain (Anand and Marmorstein,
2007). LSD-1 is recruited to its target
genes by different multiprotein com-
plexes, which drive LSD-1 activity toward
mono- and dimethylated H3K9 or K4,
leading to context-dependent transcrip-
tional activation or repression (Shi et al.,
2005 and Metzger et al., 2005).
The other class of HDMs got their name
from the jumonji gene, which was identi-
fied by a mouse gene trap approach as
essential for the development of multiple
tissues (Takeuchi, 1997). Over 100
proteins from bacteria to mammals
contain a JmjC domain, a predicted10 Elsevier Inc.metalloenzyme catalytic motif. More re-
cently JmjC-domain-containing proteins
were identified as transcriptional coregu-
lators involved in the demethylation of
H3K9 (Tsukada et al., 2006). Five JmjC
domain subfamilies maintain histones de-
methylated, i.e., JHDM1, JHDM2, JMJD2,
JMJD3, and JARID1 (Tsukada et al.,
2006). Recently identified JmjC proteins
are JMJD6, an HDM with specificity to
H3R2me2 and H4R3me2, demonstrating
that also arginine methylation marks are
reversible (Chang et al., 2007), and the
PHD finger and JmjC-domain-containing
PHF8 protein, with specificity toward
mono- and dimethylated H3K9 and
H4K20 (Feng et al., 2010; Liu et al.,
2010). JmjC enzymes convert substrates
in a manner different from LSD1 and
also act on trimethylated lysines (Smith
and Denu, 2009). They feature a a-keto-
glutarate (a-KG) / Fe2+-dependent dioxy-
genase activity. a-KG stabilizes the
enzyme/substrate complex (Tsukada
et al., 2006) and binds the catalytic iron
center undergoing oxidative decarboxyl-
ation to give succinate as part of the reac-
tion (Smith and Denu 2009). While the
demethylation of H3 starts to be under-
stood, demethylases of other proteins,
including other histones, are with a few
exceptions (Chang et al., 2007; Feng
et al., 2010; Liu et al., 2010) still largely
unknown (Figure 1).
Figure 2. Chemical Structures of SAM, FAD,
and a-KG
Red ring on SAM highlights the reactive sulfur
atom. Arrows on FAD highlight the nitrogen atoms,
which are protonized in FADH2.
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and HDMs Depends on the Cellular
Energy Status
The activity of HMTs and HDMs requires
specific metabolic coenzymes (Tsukada
et al., 2006; Anand and Marmorstein,
2007; Smith and Denu, 2009), whose
biosynthesis is dependent on intracellular
ATP levels (Figures 2 and 3).
S-Adenosyl-methionine (SAM) is the
coenzyme involved in reactions with
methyl group transfer (Smith and Denu,
2009). The methyl group attached to the
sulfur atom in SAM is chemically reactive
(Figure 2). This allows donation of this
group to an acceptor substrate in trans-
methylation reactions, catalyzed bymeth-
yltransferases and involving various
acceptors like nucleic acids, proteins,
and lipids. SAM is produced in the cytosol
by the reaction between methionine and
ATP catalyzed by S-adenosyl methionine
transferase (MAT), and potentially could
link energy homeostasis to the methyla-
tion of lysines and arginines in proteins
and cytosines in DNA (Figure 3). Recently
MAT was detected in the nucleus, where
its presence correlated with histone
H3K27 trimethylation, suggesting that it
controls the local SAM supply (Reytor
et al., 2009). By taking part in methylation
reactions, SAM is demethylated to S-ad-
enosyl-homocysteine (S-AdoHCy), which
is then converted to homocysteine (Hcy)
by S-adenosyl-homocysteinase (AHCY).
Hcy can then be either recycled back tomethionine by 5-methyltetrahydrofolate-
homocysteine methyl transferase (MTR)
through transfer of a methyl group from
5-methyltetrahydrofolate (5-MTHF) (Fin-
kelstein and Martin, 2000), or fully metab-
olized to cysteine and pyruvate by two
rounds of transsulfuration reactions cata-
lyzed by cystathionine-b-synthase (CBS)
and cystathionine-g-lyase (CTH) (Finkel-
stein and Martin, 2000). High intracellular
energy levels increase SAMconcentration
and DNA methyl transferase (DNMT)
activitywith impact on global DNAmethyl-
ation (Chiang et al., 2009); whether HMT
activity and histone methylation are also
affected is still unclear. Furthermore, it is
not established whether physiological
changes in energy levels, such as those
induced by diet and exercise, change
SAM levels. The fact that anaplerotic diets
increase intracellular energy and SAM
levels and thereby improve adult polyglu-
cosan body disease, characterized by
dysfunctional glycogen metabolism and
diminished methionine levels (Roe et al.,
2010), argues that this is, however, the
case.
Methylation-independent SAM metab-
olism can also influence transcription.
SAM can be decarboxylated by SAM
decarboxylase (SAM-DC) to decarboxy-
SAM (DC-SAM) and enter the polyamine
cycle (Figure 3). Polyamines are abundant
multivalent organic cations, largely bound
to RNA and DNA, that regulate many
cellular functions, including transcription.
Interestingly, mice transgenic for the
rate-limiting enzyme in the polyamine
pathway, spermine/spermidine N1 ace-
tyltransferase (SSAT), have an improved
metabolic profile, as the accelerated poly-
amine flux enhances ATP consumption
(Pirinen et al., 2007).
To catalyze demethylation reactions,
the LSD1 or the Jumonji domain classes
of HDMs require different metabolic
cofactors, flavin adenine dinucleotide
(FAD) (Anand and Marmorstein, 2007)
and a-KG (Tsukada et al., 2006), respec-
tively. FAD is a redox coenzyme existing
in two different redox states, involved in
several important reactions inmetabolism.
FADconsistsof a riboflavinmoiety (vitamin
B2) bound to the phosphate group of ADP
(Figure 2), thus clearly requiring ATP to be
synthesized. Starting from riboflavin, flavin
mononucleotide (FMN) is first generated
by riboflavin kinase (RFK)-dependent
phosphorylation. FMN is then convertedCell Metabolism 1to FAD by FAD synthase (FLAD), which
transfers an AMP moiety from an ATP
molecule to the FMN (Figure 3). The
reduced form of FAD, FADH2, is an energy
carrier. When oxidized back to FAD,
FADH2 sends its two high-energy elec-
trons through the electron transport chain
(ETC) to produce ATP by oxidative phos-
phorylation. Any oxidoreductase enzyme
that, like LSD1, uses FAD as an electron
carrier is called a flavoprotein. Flavopro-
teins are essential inmanymetabolic reac-
tions, as illustrated by the enzyme
complex succinate dehydrogenase
(complex II) that oxidizes succinate to
fumarate in the citric acid cycle, thereby
reducing FAD to FADH2. Other well-
studied flavoproteins include acyl CoA
dehydrogenase,a-ketoglutarate dehydro-
genase (a-KGDH), andacomponent of the
pyruvate dehydrogenase complex, illus-
trating the potential link between LSD1
and intermediary metabolism (Figure 3).
a-KG (Figure 2), the coenzyme of
the JmjC class of HDMs (Tsukada
et al., 2006), is a key intermediate in the
Krebs cycle, coming after isocitrate and
before succinylCoA.Anaplerotic reactions
replenish the cycle at this juncture by
synthesizing a-KG through the action of
glutamate dehydrogenase on glutamate.
a-KG is the substrate of the a-KGDH reac-
tion by which it is converted in succinyl-
CoA in the presence of FAD and NAD
(Figure 3), a critical and highly regulated
step of the Krebs cycle mainly controlled
by feedback regulation. Succinyl-CoA,
FADH2, and NADH have all been shown
to inhibit the reaction (Smith et al., 1974).
Interestingly, a-KGDH is also inhibited by
high intracellular ATP levels (Smith et al.,
1974) (Figure 3).
Based on the dependence of HMTs and
HDMs on metabolic coenzymes, whose
availability is governed by the intracellular
energy content, these effectors of revers-
ible methylation could in theory repro-
gram gene expression in function of the
metabolic milieu. But, however tempting
this hypothesis is, much further work is
required to unequivocally establish
whether these coenzymes are rate-
limiting under physiological conditions.
Methylation/Demethylation
in the Pathogenesis of Metabolic
Disorders
The first SET-domain HMT to be studied
for its role in metabolism was MLL3,2, October 6, 2010 ª2010 Elsevier Inc. 323
Figure 3. Schematic Representation of How Cofactor Biosynthesis Is Dependent on Intracellular Energy Status
The ATP produced by the intracellular metabolism of nutrients is the key molecule for the biosynthesis of cofactors. MAT converts methionine to SAM by using
ATP. RFK and FLAD use also ATP to synthesize FAD from riboflavin. High intracellular ATP levels in contrast inhibit a-KGDH, a key enzyme in the TCA (tri-carbox-
ylic-acid cycle) that converts a-ketoglutarate to succinyl-CoA (Smith et al., 1974). Words depicted in blue indicate precursors for coenzymes biosynthesis; words
in green indicate coenzymes directly involved in methylation (SAM) and/or demethylation (FAD and a-KG) reactions. Abbreviations are found in the text.
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(MLL) family (Ansari and Mandal, 2010).
MLL3 is a component of the ASC-2/
NCOA6 (ASCOM) complex, which
possesses HMT activity toward H3K4
and is involved in transcriptional coactiva-
tion (Lee et al., 2008a). MLL3/ mice
have less white adipose tissue, associ-
ated with a favorable metabolic profile.
The MLL3/ mice are also resistant to
high-fat diet-induced hepatosteatosis
because of the role of ASCOM in coacti-
vating the liver X receptor (Lee et al.,
2008b). In line with these observations
for MLL3, SETDB1 has also been shown
to inhibit adipogenesis via Wnt-depen-
dent inactivation of PPARa transcriptional
activity (Takada et al., 2007).
The SET7 HMT has been recently
suggested to be involved in the patho-
genesis of vascular complications of dia-
betes (El-Osta et al., 2008; Brasacchio
et al., 2009). Transient hyperglycemia
causes both in vitro and in vivo a sus-
tained expression and activation of the
transcription factor NFkB-p65. This is
associated on the one hand with SET7
recruitment and H3K4 monomethylation
(El-Osta et al., 2008) and on the other324 Cell Metabolism 12, October 6, 2010 ª20hand with persistent H3K9 demethyla-
tion and recruitment of LSD1 to the
NFkB-p65 promoter (Brasacchio et al.,
2009). Another study also links LSD1
and the vascular impact of diabetes
(Reddy et al., 2008). In mouse vascular
smooth muscle cells (mVSMC) from db/
db mice, a mouse model of diabesity,
both the basal and Tumor necrosis
factor-a-induced expression of the
inflammatory genes monocyte chemoat-
tractant protein 1 (MCP-1) and inter-
leukin 6 (IL-6) are increased. This is
associated with an increase in the acti-
vating H3K4 dimethylation mark and
reduced LSD1 recruitment to the
promoters. Interestingly, high-glucose
treatment recapitulates this in vivo
observation in cultured human VSMC,
suggesting that glucose by itself
increases the expression of inflammatory
genes, like MCP-1 and IL-6, through
alterations in histone methylation.
Although it is tempting to speculate
that metabolic alterations in diabetes,
through changing the levels/activity of
metabolic coenzymes, could impact on
HMT/HDM activity, firm evidence in
support of this hypothesis is still missing.10 Elsevier Inc.One of the best characterized JmjC-
domain-containing HDMs is JHDM2a/
KDM3A, which has been recently demon-
strated to play a role in metabolism, as
two coinciding studies show that
JHDM2a/ mice develop to become
obese (Tateishi et al., 2009; Inagaki
et al., 2009). The mechanisms proposed
in these two studies are different. Tateishi
et al. attribute the obesity to impaired
brown adipose tissue function, likely due
to a reduced expression of genes
involved in energy metabolism, as UCP1
and PPARa, and an impaired b-adren-
ergic signaling (Tateishi et al., 2009). Inter-
estingly, the JHDM2a/ mice developed
by Inagaki also show a full-blown meta-
bolic syndrome, but brown adipose tissue
was not affected (Inagaki et al., 2009). In
contrast, a set of genes was specifically
reduced in white adipose tissue, including
the anti-adipogenic transcription factor
COUP-TFII (Xu et al., 2008), an inhibitor
of fat storage like ApoC1 (Jong et al.,
2001), the insulin-dependent glucose
transporter GLUT4 (Stenbit et al., 1997),
and ADAMTS9, a gene associated to
type 2 diabetes by genome-wide associa-
tion studies (Zeggini et al., 2008). As both
Figure 4. Schematic Representation of How Intracellular Nutrient
Signals Are Integrated to Reprogram Transcription
Solid arrows indicate activation of transcription; dotted lines indicate inhibition
of transcription. Words depicted in blue indicate precursors for coenzymes
biosynthesis; words in green indicate coenzymes directly involved in methyla-
tion (SAM) and/or demethylation (FAD and a-KG) reactions. Abbreviations are
found in the text.
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not mutually exclusive, fur-
ther studies are required to
clarify the molecular path-
ways involved in the pheno-
typic changes in JHDM2a/
mice.
Although all these studies
suggest metabolic functions
of HMTs/HDMs, they are far
from establishing how these
enzymes are integrated in
metabolic control. In fact, no
hard biochemical evidence is
provided that the levels of
the metabolic cofactors
(SAM, FAD and a-KG) were
affected by the metabolic
changes, a conditio sine qua
non to establish the link
between methylation/deme-
thylation and metabolism.
Furthermore, it is unclear
how HMTs/HDMs are selec-
tively targeted to certain
promoters (e.g., NFkB-p65
gene) to achieve highly
specific effects on certaingenes but not others. From the apparent
contradictory results, showing on the
one hand LSD1 recruitment and persis-
tent demethylation of H3K9 (Brasacchio
et al., 2009) and on the other hand LSD1
depletion and hypermethylation of H3K4
(Reddy et al., 2008), it also emerges that
the role of high glucose in the control of
LSD1 activity and methylation is complex
and contentious. Another key question is
how transient changes in glycemia induce
long-lasting alterations in chromatin state.
Although this so-called ‘‘metabolic
memory’’ concept has been invoked to
explain the sustained legacy effect of
blood glucose control observed in the
Diabetes Control and Complications Trial
and the United Kingdom Prospective Dia-
betes Study (Nathan et al., 2005; Holman
et al., 2008), further mechanistic work is
required to establish a role for HMTs/
HDMs in this phenomenon.
Conclusions and Future
Perspectives
The epigenome has been hypothesized to
provide an important part of the interface
between the environment and the regula-
tion of gene expression (reviewed by
Ladurner, 2006 and Feinberg, 2007).
Clearly, one of the most important envi-ronmental factors is the availability of
energy. In the body, energy-rich
substrates, such as carbohydrates and
fats, are converted into ATP, with con-
comitant increases in the levels of metab-
olites such as acetyl-CoA, NAD+/NADH,
SAM, a-KG, and FAD by processes like
glycolysis, fatty acid oxidation, and oxida-
tive phosphorylation. These metabolites,
in turn, are the high-energy substrates
used as coenzymes by chromatin and
DNA-modifying enzymes to drive epige-
neticmodifications and alter gene expres-
sion (Ladurner, 2006; Tsukada et al.,
2006; Anand and Marmorstein, 2007;
Feige and Auwerx, 2007; Wellen et al.,
2009) (Figure 4). Sensing these interme-
diary factors is hence a prime way to
inform cells about the energy availability.
For the lysine acetyl transferases
(KATs) and deacetylases (KDACs), solid
evidence is emerging that they act as
real energy sensors that are respectively
activated by high and low intracellular
energy levels, and that they translate
these metabolic signals into alterations
in chromatin structure and transcription
(reviewed by Feige and Auwerx, 2007;
Dominy et al., 2010; Jeninga et al., 2010;
Zhao et al., 2010). Furthermore, the char-
acterization of these KATs and KDACsCell Metabolism 12, October 6,has demonstrated a role for
some of them in the control
metabolic flexibility and
linked them to the pathogen-
esis of common complex
disorders of the metabolic,
cardiovascular, and nervous
systems. In analogy to the
KATs and KDACs, it is
tempting to speculate that
the HMTs and HDMs could
fulfil similar functions. The
phenotypic characterization
of various genetically engi-
neered mouse models for
the HMTs and HDMs, which
show some metabolic abnor-
malities, argues that they
could in fact control meta-
bolic processes. Further
support for such a role is
provided by studies in
C. elegans and D. mela-
nogaster, that assign a role
for HMTs/HDMs in longevity
(Chen et al., 2009; Greer
et al., 2010; Siebold et al.,
2010), which traditionally hasbeen linked to metabolism (reviewed by
Bordone and Guarente 2005; Houtkooper
et al., 2010).
Despite the implication of HMTs and
HDMs in metabolic control, at present
evidence to support that they are bona
fide energy sensors that directly synchro-
nize metabolic information with transcrip-
tion is still circumstantial. To turn this
speculation into hard facts, further
research is required. First, the depen-
dence of HMTs/HDMs on their metabolic
coenzymes was often determined in
highly artificial test-tube cell-free condi-
tions and therefore needs also to be
established in cellular systems and in the
intact organism. Evidence how the rapidly
changing physiological and develop-
mental homeostatic context affects the
dynamic levels of metabolic coenzymes,
and how this then is integrated by the
HMTs/HDMs to alter transcriptional
homeostasis in a highly specific manner,
is also lacking. Within this context, partic-
ular attention should be given to solve the
apparent contradiction that the cellular
energy levels positively regulate the
synthesis of both coenzymes for HMTs
and HDMs. Furthermore, clarification is
required about how these nuclear local-
ized HMTs and HDMs capture these2010 ª2010 Elsevier Inc. 325
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produced in different cellular compart-
ments (mitochondria and cytoplasm).
Finally, the temporal nature of an eventual
coupling between metabolic changes,
coenzyme levels, HMT/HDM activity,
histone methylation, and changes in
gene expression needs to be solved. In
other words, how can extremely dynamic
metabolic processes adapt transcription
over extended periods? In the absence
of unequivocal evidence for the role of
HMTs and HDMs as energy sensors, the
simple alternative that energy sensing
involves other factors that ultimately
transmit this information to transcription
factors in the nucleus, which then recruit
HMTs and HDMs to specific genomic
loci to alter gene expression and maintain
metabolic homeostasis, remains a safe
explanation.
Despite these reservations, we think
that over the next years a number of
studies will emerge that will help us to
unequivocally define whether and how
HMTs/HDMs contribute to metabolic
control. We can only hope that, in analogy
to the KATs and KDACs, these HMTs and
HDMs may also provide us with new
targets for prevention and treatment of
metabolic diseases.
ACKNOWLEDGMENTS
This work was supported by grants of the Ecole
Polytechnique Fe´de´rale de Lausanne, Swiss
National Science Foundation, NIH (DK59820),
and the European Research Council Ideas pro-
gramme (Sirtuins; ERC-2008-AdG23118). We
thank the reviewers for their helpful suggestions.
REFERENCES
Anand, R., and Marmorstein, R. (2007). J. Biol.
Chem. 282, 35425–35429.
Ansari, K.I., and Mandal, S.S. (2010). FEBS J. 277,
1790–1804.
Berger, S.L. (2007). Nature 447, 407–412.
Bernstein, B.E., Meissner, A., and Lander, E.S.
(2007). Cell 128, 669–681.
Bordone, L., and Guarente, L. (2005). Nat. Rev.
Mol. Cell Biol. 6, 298–305.
Brasacchio, D., Okabe, J., Tikellis, C., Balcerczyk,
A., George, P., Baker, E.K., Calkin, A.C., Brownlee,
M., Cooper, M.E., and El-Osta, A. (2009). Diabetes
58, 1229–1236.
Chang, B., Chen, Y., Zhao, Y., and Bruick, R.K.
(2007). Science 318, 444–447.
Chawla, A., Repa, J.J., Evans, R.M., and Mangels-
dorf, D.J. (2001). Science 294, 1866–1870.326 Cell Metabolism 12, October 6, 2010 ª20Chen, S.,Whetstine, J.R., Ghosh, S., Hanover, J.A.,
Gali, R.R., Grosu, P., and Shi, Y. (2009). Proc. Natl.
Acad. Sci. USA 106, 1496–1501.
Chiang, E.P., Wang, Y.C., Chen, W.W., and
Tang, F.Y. (2009). J. Clin. Endocrinol. Metab.
94, 1017–1025.
Chuikov, S., Kurash, J.K., Wilson, J.R., Xiao, B.,
Justin, N., Ivanov, G.S., McKinney, K., Tempst, P.,
Prives, C., Gamblin, S.J., et al. (2004). Nature 432,
353–360.
Dominy, J.E., Jr., Lee, Y., Gerhart-Hines, Z., and
Puigserver, P. (2010). Biochim. Biophys. Acta.
Proteins Proteomics 1804, 1676–1683.
El-Osta, A., Brasacchio, D., Yao, D., Pocai, A.,
Jones, P.L., Roeder, R.G., Cooper, M.E., and
Brownlee, M. (2008). J. Exp. Med. 205, 2409–2417.
Feige, J.N., and Auwerx, J. (2007). Trends Cell Biol.
17, 292–301.
Feinberg, A.P. (2007). Phenotypic plasticity and the
epigenetics of human disease. Nature 447,
433–440.
Feng, W., Yonezawa, M., Ye, J., Jenuwein, T.,
and Grummt, I. (2010). Nat. Struct. Mol. Biol. 17,
445–450.
Finkelstein, J., andMartin, J. (2000). Int. J. Biochem.
Cell Biol. 32, 385–389.
Francis, G.A., Fayard, E., Picard, F., and Auwerx, J.
(2003). Annu. Rev. Physiol. 65, 261–311.
Greer, E.L., Maures, T.J., Hauswirth, A.G., Green,
E.M., Leeman, D.S., Maro, G.S., Han, S., Banko,
M.R., Gozani, O., and Brunet, A. (2010). Nature
466, 383–387.
Haberland, M., Montgomery, R.L., and Olson, E.N.
(2009). Nat. Rev. Genet. 10, 32–42.
Holman, R.R., Paul, S.K., Bethel, M.A., Matthews,
D.R., and Neil, H.A. (2008). N. Engl. J. Med. 359,
1577–1589.
Houtkooper, R.H., Williams, R.W., and Auwerx, J.
(2010). Cell 142, 9–14.
Huang, J., Dorsey, J.,Chuikov, S., Pe´rez-Burgos, L.,
Zhang, X., Jenuwein, T., Reinberg, D., and Berger,
S.L. (2010). J. Biol. Chem. 285, 9636–9641.
Inagaki, T., Tachibana, M., Magoori, K., Kudo, H.,
Tanaka, T., Okamura, M., Naito, M., Kodama, T.,
Shinkai, Y., and Sakai, J. (2009). Genes Cells 14,
991–1001.
Jeninga, E.H., Schoonjans, K., and Auwerx, J.
(2010). Oncogene, in press.
Jenuwein, T., and Allis, C.D. (2001). Science 293,
1074–1080.
Jones, R.S., and Gelbart, W.M. (1993). Mol. Cell.
Biol. 13, 6357–6366.
Jong, M.C., Voshol, P.J., Muurling, M., Dahlmans,
V.E., Romijn, J.A., Pijl, H., and Havekes, L.M.
(2001). Diabetes 50, 2779–2785.
Kouzarides, T. (2007). Cell 128, 693–705.
Ladurner, A.G. (2006). Mol. Cell 24, 1–11.
Laskowski, R.A., and Thornton, J.M. (2008). Nat.
Rev. Genet. 9, 141–151.10 Elsevier Inc.Lee, J., Saha, P.K., Yang, Q.H., Lee, S., Park, J.Y.,
Suh, Y., Lee, S.K., Chan, L., Roeder, R.G., and Lee,
J.W. (2008a). Proc. Natl. Acad. Sci. USA 105,
19229–19234.
Lee, S., Lee, J., Lee, S.K., and Lee, J.W. (2008b).
Mol. Endocrinol. 22, 1312–1319.
Ling, C., and Groop, L. (2009). Diabetes 58, 2718–
2725.
Liu, W., Tanasa, B., Tyurina, O.V., Zhou, T.Y.,
Gassmann, R., Liu, W.T., Ohgi, K.A., Benner, C.,
Garcia-Bassets, I., Aggarwal, A.K., et al. (2010).
Nature 466, 508–512.
Metzger, E., Wissmann, M., Yin, N., Mu¨ller, J.M.,
Schneider, R., Peters, A.H., Gu¨nther, T., Buettner,
R., and Schu¨le, R. (2005). Nature 437, 436–439.
Munro, S., Khaire, N., Inche, A., Carr, S., and La
Thangue, N.B. (2010). Oncogene 29, 2357–2367.
Nathan, D.M., Cleary, P.A., Backlund, J.Y., Gen-
uth, S.M., Lachin, J.M., Orchard, T.J., Raskin, P.,
and Zinman, B.; Diabetes Control and Complica-
tions Trial/Epidemiology of Diabetes Interventions
and Complications (DCCT/EDIC) Study Research
Group. (2005). N. Engl. J. Med. 353, 2643–2653.
Pirinen, E., Kuulasmaa, T., Pietila¨, M., Heikkinen, S.,
Tusa, M., Itkonen, P., Boman, S., Skommer, J., Vir-
kama¨ki, A., Hohtola, E., et al. (2007). Mol. Cell. Biol.
27, 4953–4967.
Rea, S., Eisenhaber, F., O’Carroll, D., Strahl, B.D.,
Sun, Z.W., Schmid, M., Opravil, S., Mechtler, K.,
Ponting, C.P., Allis, C.D., and Jenuwein, T.
(2000). Nature 406, 593–599.
Reddy, M., Villeneuve, L.M., Wang, M., Lanting, L.,
and Natarajan, R. (2008). Circ. Res. 103, 615–623.
Reytor, E., Pe´rez-Miguelsanz, J., Alvarez, L.,
Pe´rez-Sala, D., and Pajares, M.A. (2009). FASEB
J. 23, 3347–3360.
Roe, C.R., Bottiglieri, T., Wallace, M., Arning, E.,
and Martin, A. (2010). Mol. Genet. Metab., Epub
ahead of print.
Rosenfeld, M.G., Lunyak, V.V., and Glass, C.K.
(2006). Genes Dev. 20, 1405–1428.
Ruthenburg, A.J., Li, H., Patel, D.J., and Allis, C.D.
(2007). Nat. Rev. Mol. Cell Biol. 8, 983–994.
Shi, Y., Lan, F., Matson, C., Mulligan, P.,
Whetstine, J.R., Cole, P.A., Casero, R.A., and
Shi, Y. (2004). Cell 119, 941–953.
Shi, Y.J., Matson, C., Lan, F., Iwase, S., Baba, T.,
and Shi, Y. (2005). Mol. Cell 19, 857–864.
Siebold, A.P., Banerjee, R., Tie, F., Kiss, D.L.,
Moskowitz, J., and Harte, P.J. (2010). Proc. Natl.
Acad. Sci. USA 107, 169–174.
Smith, C., Bryla, J., and Williamson, J.R. (1974).
J. Biol. Chem. 249, 1497–1505.
Smith, C.L., and O’Malley, B.W. (2004). Endocr.
Rev. 25, 45–71.
Smith, B.C., and Denu, J.M. (2009). Biochim.
Biophys. Acta 1789, 45–57.
Spiegelman, B.M., and Heinrich, R. (2004). Cell
119, 157–167.
Stassen, M., Bailey, D., Nelson, S., Chinwalla, V.,
and Harte, P.J. (1995). Mech. Dev. 52, 209–223.
Cell Metabolism
PerspectiveStenbit, A.E., Tsao, T.S., Li, J., Burcelin, R.,
Geenen, D.L., Factor, S.M., Houseknecht, K.,
Katz, E.B., and Charron, M.J. (1997). Nat. Med. 3,
1096–1101.
Subramanian, K., Jia, D., Kapoor-Vazirani, P.,
Powell, D.R., Collins, R.E., Sharma, D., Peng, J.,
Cheng, X., and Vertino, P.M. (2008). Mol. Cell 30,
336–347.
Suzuki, M.M., and Bird, A. (2008). Nat. Rev. Genet.
9, 465–476.
Takada, I., Mihara, M., Suzawa, M., Ohtake, F.,
Kobayashi, S., Igarashi, M., Youn, M.Y., Take-
yama, K., Nakamura, T., Mezaki, Y., et al.
(2007). Nat. Cell. Biol. 11, 1273–1285.Takeuchi, T. (1997). Dev. Growth Differ. 39,
127–134.
Tateishi, K., Okada, Y., Kallin, E.M., and Zhang, Y.
(2009). Nature 458, 757–761.
Teyssier, C., Ma, H., Emter, R., Kralli, A., and
Stallcup, M.R. (2005). Genes Dev. 19, 466–473.
Tschiersch, B., Hofmann, A., Krauss, V., Dorn, R.,
Korge, G., and Reuter, G. (1994). EMBO J. 13,
3822–3831.
Tsukada, Y., Fang, J., Erdjument-Bromage, H.,
Warren, M.E., Borchers, C.H., Tempst, P., and
Zhang, Y. (2006). Nature 439, 811–816.
Vakoc, C.R., Mandat, S.A., Olenchock, B.A., and
Blobel, G.A. (2005). Mol. Cell 19, 381–391.Cell Metabolism 1Wellen, K., Hatzivassiliou, G., Sachdeva, U.M.,
Bui, T.V., Cross, J.R., and Thompson, C.B.
(2009). Science 324, 1076–1080.Xu, Z., Yu, S., Hsu, C.H., Eguchi, J., and Rosen,
E.D. (2008). Proc. Natl. Acad. Sci. USA 105,
2421–2426.Zeggini, E., Scott, L.J., Saxena, R., Voight, B.F.,
Marchini, J.L., Hu, T., de Bakker, P.I., Abecasis,
G.R., Almgren, P., Andersen, G., et al. (2008).
Nat. Genet. 40, 638–645.Zhao, S., Xu, W., Jiang, W., Yu, W., Lin, Y., Zhang,
T., Yao, J., Zhou, L., Zeng, Y., Li, H., et al. (2010).
Science 327, 1000–1004.2, October 6, 2010 ª2010 Elsevier Inc. 327
